Alteration of SHP-1/p-STAT3 signaling: A potential target for anticancer therapy

Tzu Ting Huang, Jung Chen Su, Chun Yu Liu*, Chung Wai Shiau, Kuen Feng Chen

*此作品的通信作者

研究成果: Review article同行評審

45 引文 斯高帕斯(Scopus)

摘要

The Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 1 (SHP-1), a non-receptor protein tyrosine phosphatase, has been reported as a negative regulator of phosphorylated signal transducer and activator of transcription 3 (STAT3) and linked to tumor development. In this present review, we will discuss the importance and function of SHP-1/p-STAT3 signaling in nonmalignant conditions as well as malignancies, its cross-talk with other pathways, the current clinical development and the potential role of inhibitors of this pathway in anticancer therapy and clinical relevance of SHP-1/p-STAT3 in cancers. Lastly, we will summarize and highlight work involving novel drugs/compounds targeting SHP-1/p-STAT3 signaling and combined strategies that were/are discovered in our and our colleagues’ laboratories.

原文English
文章編號1234
期刊International Journal Of Molecular Sciences
18
發行號6
DOIs
出版狀態Published - 8 6月 2017

指紋

深入研究「Alteration of SHP-1/p-STAT3 signaling: A potential target for anticancer therapy」主題。共同形成了獨特的指紋。

引用此